Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYLM's EV-to-EBITDA is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 8.99 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Central Asia Lumeichun Biotechnology (OTCPK:ZYLM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Central Asia Lumeichun Biotechnology's PE Ratio (TTM) for today is calculated as:
Central Asia Lumeichun Biotechnology's share price for today is $0.1636.
Central Asia Lumeichun Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.335.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology EV-to-EBITDA Chart
For the Farm Products subindustry, Central Asia Lumeichun Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Asia Lumeichun Biotechnology EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Central Asia Lumeichun Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Central Asia Lumeichun Biotechnology's EV-to-EBITDA falls into.
Central Asia Lumeichun Biotechnology's current Enterprise Value is $0.10 Mil.
Central Asia Lumeichun Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology (ZYLM) has a EV-to-EBITDA of 1.55 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Central Asia Lumeichun Biotechnology.
Is Central Asia Lumeichun Biotechnology's EV-to-EBITDA too high?
Central Asia Lumeichun Biotechnology's current EV-to-EBITDA is 1.55. The Consumer Packaged Goods industry median EV-to-EBITDA is 8.99. Central Asia Lumeichun Biotechnology's value of 1.55 is 82.8% below this industry median.
How does Central Asia Lumeichun Biotechnology's EV-to-EBITDA compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's EV-to-EBITDA of 1.55 can be compared against companies in the Consumer Packaged Goods industry. The industry median EV-to-EBITDA is 8.99. Central Asia Lumeichun Biotechnology's value of 1.55 is 82.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 8.99, based on 1,701 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Asia Lumeichun Biotechnology's current EV-to-EBITDA of 1.55 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Central Asia Lumeichun Biotechnology. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Asia Lumeichun Biotechnology's current EV-to-EBITDA is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current EV-to-EBITDA of 1.55. The current EV-to-EBITDA is 1.55 and 82.8% below the Consumer Packaged Goods industry median of 8.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current EV-to-EBITDA is 1.55 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYLM has been successfully added to your 
